Skip to main content
    N

    Neuronetics Inc (STIM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.39
    -0.04 (-2.80%)

    Market Cap: $134.10M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Neuronetics Inc (STIM) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Neuronetics (STIM) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Neuronetics reported EPS of -$0.02, above the -$0.08 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    62%(21/34)
    Avg Surprise
    +1.81%
    Streak
    4 Q

    Upcoming Estimates

    Reports Mar 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.06
    Range-$0.07 - -$0.05
    6 analysts
    Revenue Consensus
    $45.13M
    Range$43.12M - $46.73M
    7 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.08
    Range-$0.10 - -$0.07
    3 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.08-4.1%
    60d ago-$0.08-4.1%
    30d ago-$0.09+3.9%
    7d ago-$0.09+3.9%
    Current-$0.08
    Revenue Consensus
    $37.73M
    Range$37.50M - $37.90M
    3 analysts

    Next Report

    STIM has an expected report date of Mar 15, 2027.

    STIM Earnings Call

    The latest STIM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 34 quarters below that had an estimate, STIM beat 21, missed 12 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $41.96M, up 12.5% from $37.30M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.02-$0.08N/A+75.00%BeatN/A12 up, 0 downNov 4, 2026$41.96M
    Jun 30, 2026-$0.05-$0.11-$0.13 - -$0.11+54.55%BeatN/A42 up, 0 downAug 11, 2026$41.57M
    Mar 31, 2026-$0.15-$0.17-$0.18 - -$0.17+11.76%BeatN/A30 up, 2 downMay 5, 2026$34.45M
    Dec 31, 2025-$0.10-$0.11-$0.12 - -$0.10+9.09%BeatN/A20 up, 1 downMar 17, 2026$41.78M
    Sep 30, 2025-$0.13-$0.12-$0.13 - -$0.11-8.33%MissN/A20 up, 2 downNov 4, 2025$37.30M
    Jun 30, 2025-$0.15-$0.08-$0.08 - -$0.08-87.50%MissN/A20 up, 0 downAug 5, 2025$38.11M
    Mar 31, 2025-$0.21-$0.12-$0.13 - -$0.11-75.00%MissN/A33 up, 0 downMay 6, 2025$31.98M
    Dec 31, 2024-$0.33-$0.24-$0.28 - -$0.23-37.50%MissN/A40 up, 0 downMar 4, 2025$22.49M
    Sep 30, 2024-$0.44-$0.23-$0.26 - -$0.20-91.30%MissN/A40 up, 0 downNov 12, 2024$18.53M
    Jun 30, 2024-$0.33-$0.27-$0.27 - -$0.27-22.22%MissN/A40 up, 0 downAug 12, 2024$16.45M
    Mar 31, 2024-$0.27-$0.31-$0.37 - -$0.26+12.90%BeatN/A40 up, 0 downMay 7, 2024$17.42M
    Dec 31, 2023-$0.19-$0.26-$0.27 - -$0.25+26.92%BeatN/A40 up, 0 downMar 5, 2024$20.31M
    Sep 30, 2023-$0.33-$0.28-$0.35 - -$0.28-17.86%MissN/A40 up, 0 downNov 7, 2023$17.88M
    Jun 30, 2023-$0.17-$0.35-$0.36 - -$0.31+51.43%BeatN/A40 up, 0 downAug 8, 2023$17.61M
    Mar 31, 2023-$0.38-$0.39-$0.43 - -$0.35+2.56%BeatN/A40 up, 0 downMay 9, 2023$15.54M
    Dec 31, 2022-$0.30-$0.38-$0.43 - -$0.30+21.05%BeatN/A40 up, 0 downMar 7, 2023$18.20M
    Sep 30, 2022-$0.28-$0.42-$0.45 - -$0.41+33.33%BeatN/A50 up, 0 downNov 8, 2022$16.50M
    Jun 30, 2022-$0.39-$0.41-$0.44 - -$0.38+4.88%BeatN/A50 up, 0 downAug 2, 2022$16.33M
    Mar 31, 2022-$0.41-$0.40-$0.42 - -$0.37-2.50%MissN/A50 up, 0 downMay 12, 2022$14.18M
    Dec 31, 2021-$0.29-$0.32-$0.34 - -$0.29+9.38%BeatN/A5N/AMar 8, 2022$15.02M
    Sep 30, 2021-$0.31-$0.30-$0.34 - -$0.27-3.33%MissN/A5N/ANov 9, 2021$13.80M
    Jun 30, 2021-$0.29-$0.24-$0.25 - -$0.23-20.83%MissN/A5N/AAug 3, 2021$14.20M
    Mar 31, 2021-$0.31-$0.31-$0.35 - -$0.270.00%In lineN/A5N/AMay 4, 2021$12.29M
    Dec 31, 2020-$0.19-$0.24-$0.30 - -$0.19+20.83%BeatN/A5N/AMar 2, 2021$15.58M
    Sep 30, 2020-$0.18-$0.28-$0.32 - -$0.23+35.71%BeatN/A5N/ANov 2, 2020$12.45M
    Jun 30, 2020-$0.41-$0.50-$0.54 - -$0.48+18.00%BeatN/A4N/AAug 4, 2020$9.74M
    Mar 31, 2020-$0.63-$0.46-$0.60 - -$0.36-36.96%MissN/A5N/AMay 5, 2020$11.48M
    Dec 31, 2019-$0.41-$0.44-$0.48 - -$0.41+6.82%BeatN/A5N/AMar 3, 2020$17.36M
    Sep 30, 2019-$0.37-$0.43-$0.46 - -$0.40+13.95%BeatN/A5N/ANov 5, 2019$16.00M
    Jun 30, 2019-$0.39-$0.41-$0.43 - -$0.35+4.88%BeatN/A5N/AAug 6, 2019$16.57M
    Mar 31, 2019-$0.42-$0.40-$0.54 - -$0.35-5.00%Miss-2200.0%5N/AMay 7, 2019$12.73M
    Dec 31, 2018-$0.35-$0.37-$0.39 - -$0.33+5.41%BeatN/A5N/AMar 5, 2019$15.63M
    Sep 30, 2018-$0.29-$0.40-$1.47 - -$0.39+27.50%BeatN/A5N/ANov 6, 2018$13.74M
    Jun 30, 2018-$0.67-$0.88-$1.19 - -$0.39+23.86%BeatN/A5N/AAug 14, 2018$13.25M
    Mar 31, 2018$0.02N/AN/AN/AN/AN/AN/AN/AJun 29, 2018$10.15M
    Last 35 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.59, after -$1.37 the year before. It was -$1.29 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.59N/A
    Dec 31, 2024-$1.37N/A
    Dec 31, 2023-$1.07N/A
    Dec 31, 2022-$1.38N/A
    Dec 31, 2021-$1.20N/A
    Dec 31, 2020-$1.41N/A
    Dec 31, 2019-$1.59N/A
    Dec 31, 2018-$1.29N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,6658
    2026Q2Jun 30, 20265,5347
    2026Q1Mar 31, 20264,8416
    2025Q4Dec 31, 20255,8507
    2025Q3Sep 30, 20255,9207
    2025Q2Jun 30, 20255,5217
    2025Q1Mar 31, 20255,2378
    2024Q3Sep 30, 20243,8717

    2026Q3 Earnings Call

    Opening remarks

    Aman Patel ICR Healthcare Representative Good morning, and thank you for joining us for the Neuronetics Third Quarter 2026 Conference Call. Joining me on today's call are Neuronetics' President and Chief Executive Officer, Daniel L. Reuvers, and Chief Financial Officer, Nir Naor. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements related to our business strategy, financial and revenue guidance, and other operational issues and metrics. Actual results can differ materially from the company's expectations. For a discussion of risks and uncertainties associated with Neuronetics' business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the company's annual report on Form 10-K, which was filed in March, and the company's quarterly report on Form 10-Q for the quarter ending March 31, 2026. The company disclaims any obligation to update any forward-looking statement made during the course of this call, except as required by law. During the call, we will also discuss certain information on a non-GAAP basis, including EBITDA. Management believes that non-GAAP financial information, taken in conjunction with U.S. GAAP financial measures, provides useful information for both management and investors by excluding certain noncash and other expenses that are not indicative of trends in our operating results. Reconciliations between U.S. GAAP and non-GAAP results are presented in the tables accompanying our press release, which can be viewed on our website. With that, it is my pleasure to turn the call over to Neuronetics' President and Chief Executive Officer, Daniel L. Reuvers.

    Daniel L. Reuvers President and Chief Executive Officer Thanks, Aman, and good morning, everyone. Thank you for joining us for our third quarter 2026 earnings call. I will first walk you through the quarter, reviewing our results on each side of the business, and then I will turn it over to Nir to discuss our financial results in greater detail. I will then come back with how we are thinking about the rest of the year and the setup for 2027 before opening it up for questions. Turning to the quarter, we continued to execute against the profitability and operating cash goals we outlined earlier in the year, and we made meaningful progress on both fronts. Total revenue for the quarter was approximately $42 million, up over 12% versus the third quarter of last year. The results reflect a record quarter for NeuroStar system sales, driven by a welcome reception from customers toward our expanded go-to-market strategy, as well as continued strength within our Greenbrook clinics as we realized ongoing impacts of our revenue cycle management efforts. Diving deeper into our NeuroStar performance, let me start there. Total worldwide revenue was $15.8 million, up approximately 2% year over year.

    Frequently Asked Questions About STIM

    When is Neuronetics's next earnings date?

    Neuronetics's next earnings report is expected for Mar 15, 2027.

    Did STIM beat earnings estimates last quarter?

    Yes. Neuronetics reported EPS of -$0.02 for the quarter ended Sep 30, 2026, above the -$0.08 estimate, a 75.00% surprise.

    What EPS do analysts expect from STIM next quarter?

    The consensus EPS estimate for Neuronetics for the quarter ending Dec 31, 2026 is -$0.06 from 6 analysts, with estimates from -$0.07 to -$0.05.

    How often does STIM beat earnings estimates?

    Neuronetics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -7.24%.